Amgen recalls nearly 1 million bottles of heart drug Corlanor
Amgen has initiated a recall of approximately 1 million bottles of its heart medication, Corlanor, due to potential quality concerns in the US.
Recall Details and FDA Classification
Pharmaceutical giant Amgen is recalling nearly 1 million bottles of Corlanor (ivabradine hydrochloride) within the United States. The U.S. Food and Drug Administration (FDA) has officially classified this action as a Class II recall.
A Class II recall indicates a situation where use of the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification is standard for specific manufacturing or labeling discrepancies that do not pose an immediate life-threatening risk.
Product Information and Scope
Corlanor is a prescription medication used to manage symptoms of chronic heart failure. The scope of this recall involves a significant volume of stock, affecting distribution across multiple batches. Patients currently using the medication are advised to consult their healthcare providers regarding any necessary changes to their treatment regimen.
The recall specifically targets specific lots of the medication. Consumers and medical professionals should verify the following details against their current supplies:
- Product Name: Corlanor (ivabradine hydrochloride)
- Manufacturer: Amgen
- Recall Classification: FDA Class II
- Market: United States
Next Steps for Patients and Providers
Healthcare providers and pharmacists are being notified to identify and remove affected lots from their inventories. Patients who have received the recalled medication should not immediately stop taking their prescribed treatment without first seeking professional medical advice, as sudden discontinuation of heart medication can lead to complications.
Amgen has stated it is working closely with regulatory authorities to manage the distribution and replacement of the affected units. Further information regarding specific lot numbers and identification methods is expected to be released through official regulatory channels as the investigation continues.
